newsfilter
← Latest News
GlobeNewswire·

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash Burn of $340-370M and Cash Runway into